LGC Clinical Diagnostics Presents Seraseq and ACCURUN Range of Diagnostic Solutions

By LabMedica International staff writers
Posted on 13 Nov 2024

LGC Clinical Diagnostics (Middlesex, UK) is presenting its latest diagnostic solutions at this year’s MEDICA, including Seraseq and ACCURUN, which align with the increasing demand for personalized medicine and enhance clinical research capabilities, along with other best-in-class products across the company’s portfolio.

At MEDICA 2024, LGC is providing full access to its product brands including Technopath Clinical Diagnostics (IVD raw materials, independent quality controls, QC software solutions), SeraCare (quality controls, reference materials, biological materials, research), Biochemical Diagnostics (drugs of abuse testing), KOVA International (urinalysis controls), Maine Standards (linearity and calibration verification, calibrators, OEM PT/EQA samples), and The Native Antigen Company (viral and bacterial antigens & antibodies, reagent components).


Image: The Seraseq and ACCURUN range of diagnostic solutions are on display at MEDICA 2024 (Photo courtesy of LGC)

LGC is highlighting SeraCare’s comprehensive suite of patient-like reference materials that accelerates development, streamlines validation, and ensures confidence in the results of today’s demanding clinical genomics assays. These platform-agnostic, ground-truth reference materials can be used through all development phases to verify actionable and challenging variants as well as complex genomic signatures in patient samples. These ready-to-use reference materials cover clinically relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions. Highly multiplexed, they provide significantly more data per NGS run, saving sequencing costs. They are also available in multiple formats to suit different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE.

LGC is also presenting SeraCare’s ACCURUN molecular controls and reference materials which are whole-cell or whole-organism external controls that help monitor all aspects of molecular testing methods and provide additional confidence in laboratory test results. A well-designed QC program can help labs avoid costly false-negative or false-positive results. ACCURUN molecular controls effectively detect low-positives closer to assay-specific cutoffs, enabling better detection of assay variability. The powerful ACCURUN controls and reference materials help to ensure complete control over assay performance monitoring.

Related Links:
LGC


Latest Medica 2024 News